Soluble tumor necrosis factor-alpha receptors in the serum of endometriosis patients

Othman ER, Essam R. Othman, Daniela Hornung, Hornung D, Hussein M, Mostafa Hussein, Ibraheem I. Abdelaal, Abdelaal II, Ayat A. Sayed, Ahmed N. Fetih, Fetih AN, Ayman Al‐Hendy, Ayman Al-Hendy, Al-Hendy A
European journal of obstetrics, gynecology, and reproductive biology · 2016 · vol. 200 , pp. 1–5 · doi:10.1016/j.ejogrb.2016.02.025 · PMID:26963895 · W2287019370
Other OA: closed CC0 ⤵ 17 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

This study measured serum levels of soluble tumor necrosis factor-alpha receptors in endometriosis patients to assess their potential role in the disease.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

INTRODUCTION: We examine serum levels sTNFR-I and sTNFR-II in endometriosis patients, and their role as biomarkers of endometriosis. MATERIAL AND METHODS: Women were diagnosed with endometriosis during laparoscopy to investigate pelvic pain and/or infertility (N=62). Control group included women with pelvic pain and/or infertility, whose laparoscopy showed no abnormalities (N=55). Serum concentrations of sTNFR-I and sTNFR-II were measured using Bioplex Protein Array system. Non-parametric statistics were used. RESULTS: Endometriosis patients had significantly higher levels of sTNFR-I than controls (257.46pg/ml, IQR=2.37-1048.92 versus 130.39pg/ml, IQR=0.99-361.1 respectively, P value=0.01). For TNFR-II, difference between women with (232pg/ml, IQR=0.0-624.4), and women without (132.93pg/ml, IQR=0.0-312.81) endometriosis was not significant (P value=0.05). Early stage endometriosis patients had significantly higher level of sTNFR-I (559.13, IQR=1.82-1289.86) and sTNFR-II (248.8, IQR=0-644.65) than control women (P value is 0.01 for TNFR-I and 0.04 for TNFR-II). Levels of sTNFR-I and sTNFR-II were comparable for advanced endometriosis and controls, and between early and advanced endometriosis. As a biomarker for all- stage endometriosis, sTNFR-I produces AUC of 0.62, sensitivity of 61%, and specificity of 47.3%, at a cutoff of 81.87pg/ml. For early stage disease, sTNFR-I yields AUC of 0.68, sensitivity of 60.7%, specificity of 75%, at a cutoff of 351.22pg/ml. CONCLUSION: sTNFR-I is significantly higher in serum of endometriosis patients than controls. As an endometriosis biomarker, sTNFR-I achieves better performance for early stage disease.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Biomarkers Endometriosis Receptors, Tumor Necrosis Factor, Type I Adult Adult Biomarkers Biomarkers Endometriosis Endometriosis Endometriosis Female Female Humans Humans Menstrual Cycle Menstrual Cycle Menstrual Cycle Receptors, Tumor Necrosis Factor, Type I Receptors, Tumor Necrosis Factor, Type I Sensitivity and Specificity

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (30)

Cited by (18)

Source provenance

europepmc
last seen: 2026-10-18T06:15:09.303036+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:17:25.481383+00:00
unpaywall
last seen: 2026-10-17T06:24:38.187582+00:00
License: CC0 · commercial use OK